Gnosis by Lesaffre launches phages-based ingredient line for gut health

The first product, developed from a new technological platform from Lesaffre that targets the main drivers of pathogen—induced digestive issues—is intended to fight pathogenic bacteria responsible for serious infections.

Gnosis by Lesaffre (Marcq-En-Baroeul, France) introduceda phages-based ingredient line to help target specific pro-inflammatory or pathogenic bacteria in the gut and potentially enhance the gastrointestinal benefits of probiotics.

“Consumers recognize probiotics and how they support our digestive health and overall health,” said Philippe Caillat, Gnosis by Lesaffre’sglobal marketing director, in a press release. “That’s what pushed us to continue exploring solutions for targeted digestive disorders, such as abdominal pain, diarrhea, and gut flora restoration. Good gut health truly is the essence of a good life. We’re here to bring that to life with our new phages-based portfolio.”

The first product, developed from a new technological platform fromLesaffrethat targets the main drivers of pathogen—induced digestive issues—is intended to fight pathogenic bacteria responsible for serious infections such as E.coli, Salmonella, and Listeria.